Kojic Acid 6% | Hydroquinone 6% | Hydrocortisone 0.5% | Tretinoin 0.05%
Kojic Acid 6% | Hydroquinone 6% | Hydrocortisone 0.5% | Tretinoin 0.05% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
Kojic Acid 6% | Hydroquinone 6% | Hydrocortisone 0.5% | Tretinoin 0.05% is a compounded topical cream containing four active depigmenting and anti-inflammatory agents: high-concentration kojic acid (tyrosinase copper chelator), high-concentration hydroquinone (tyrosinase inhibitor/melanocytotoxin), low-potency hydrocortisone (corticosteroid anti-inflammatory to reduce cytokine-driven melanogenesis and retinoid irritation), and tretinoin (retinoid accelerating keratinocyte turnover). This is an intensive, multi-mechanism formulation for prescriber-directed management of resistant hyperpigmentation. Genesis Compounding prepares this as a prescription-only, patient-specific, 503A compounded preparation not FDA-approved as a compounded drug.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Kojic Acid 6% | Fungal-derived tyrosinase inhibitor that chelates copper at the tyrosinase active site, reducing melanin synthesis and providing antioxidant effects that further limit oxidative upregulation of melanogenesis. |
| Hydroquinone 6% | High-concentration phenolic depigmenting agent that competitively inhibits tyrosinase (blocking DOPA→melanin conversion), disrupts melanosome structure, inhibits DNA/RNA synthesis in melanocytes, and is selectively cytotoxic to melanocytes at higher concentrations. |
| Hydrocortisone 0.5% | Low-potency topical corticosteroid that suppresses UV-induced prostaglandins, endothelin-1, and GM-CSF that stimulate melanogenesis, while also reducing the erythema and irritation caused by hydroquinone and tretinoin. |
| Tretinoin 0.05% | Vitamin A retinoid that accelerates epidermal keratinocyte turnover to disperse and shed pigmented corneocytes, inhibits tyrosinase activity, promotes procollagen synthesis, and enhances percutaneous penetration of co-applied depigmenting agents. |
Route: Topical. Apply a thin layer to affected hyperpigmented areas once nightly as directed by the prescriber. Avoid eyes, nostrils, lips, and mucous membranes. Apply to dry skin. Daily broad-spectrum sunscreen (SPF ≥30) is required throughout the treatment period. High-concentration hydroquinone (6%) should be applied only to targeted pigmented areas, not to surrounding normal skin, to reduce risk of surrounding depigmentation.
All dosing is prescriber-determined:
- Typically applied once nightly; prescribers may initiate alternate-night use in the first 2 weeks to assess tolerability.
- Treatment cycles for high-concentration hydroquinone formulations are typically limited to 3–6 months followed by a rest period to reduce ochronosis risk.
- Sunscreen use throughout treatment is mandatory.
- Prescribers should reassess at 8–12 weeks and consider cycling therapy.
- Kojic Acid 6%: Chelates copper ions at the binuclear copper active site of tyrosinase, competitively inhibiting hydroxylation of tyrosine and oxidation of DOPA. Also scavenges free radicals that upregulate melanogenesis.
- Hydroquinone 6%: Structurally similar to melanin precursors, competitively inhibiting tyrosinase and blocking the conversion of DOPA to melanin. At this concentration additionally disrupts melanosome structure, inhibits DNA/RNA synthesis in melanocytes, and may have selective cytotoxic effects on hyperactive melanocytes. Also inhibits melanosome dispersion through dendritic projections.
- Hydrocortisone 0.5%: Binds intracellular glucocorticoid receptors, translocates to the nucleus, and inhibits transcription of pro-inflammatory cytokines (endothelin-1, prostaglandins, GM-CSF) that stimulate melanocyte activity. Additionally reduces the erythema and irritation caused by high-concentration hydroquinone and tretinoin, improving tolerability and reducing post-inflammatory hyperpigmentation risk.
- Tretinoin 0.05%: RAR/RXR nuclear receptor activation accelerates cornified cell turnover, disperses melanin granules, stimulates procollagen I and III production, and inhibits MMPs. Tretinoin also increases epidermal permeability, enhancing penetration of co-applied hydroquinone and kojic acid.
This intensive four-ingredient formulation is directed toward patients with resistant or severe melasma, post-inflammatory hyperpigmentation, or diffuse facial photoaging with significant pigment irregularity who have not adequately responded to lower-concentration depigmenting regimens. The 6% hydroquinone concentration is well above standard OTC ranges and is associated with higher efficacy but also increased risk of ochronosis with prolonged use. This formulation is a variant of the classical Kligman-type triple therapy (HQ + corticosteroid + retinoid) with added kojic acid for synergistic tyrosinase inhibition.
Monitoring: MASI score or clinical pigmentation assessment at 8–12 weeks; watch for exogenous ochronosis (blue-black skin discoloration — discontinue immediately if this develops); contact dermatitis; retinoid dermatitis; skin atrophy (from hydrocortisone with long-term use). Avoid in pregnancy.
Contraindications:
- Pregnancy and breastfeeding (tretinoin is teratogenic; hydroquinone is systemically absorbed).
- Known hypersensitivity to hydroquinone, kojic acid, corticosteroids, or retinoids.
- Active eczema, sunburn, or open wounds at application site.
Warnings & Precautions:
- Exogenous ochronosis: a rare but permanent blue-black discoloration that can occur with prolonged use of hydroquinone, especially at ≥4% concentrations; limit treatment cycles.
- Tretinoin: mandatory daily SPF ≥30 broad-spectrum sunscreen; avoid unprotected sun exposure.
- Hydrocortisone 0.5% applied long-term to facial skin may cause local skin atrophy, telangiectasia, and perioral dermatitis; limit to short treatment cycles.
- Kojic acid: can cause allergic contact dermatitis and sensitization.
Drug Interactions:
- Tretinoin: oxidized by benzoyl peroxide — avoid simultaneous application.
- Photosensitizing medications with tretinoin may increase UV-related damage.
- Topical fluorinated corticosteroids: avoid concurrent application — risk of additive hypothalamic-pituitary-adrenal (HPA) suppression (low with hydrocortisone 0.5% but relevant with extended large-area use).
Common Side Effects: Retinoid dermatitis (peeling, erythema, dryness); contact sensitization (kojic acid or hydroquinone); photosensitivity; nail hyperpigmentation (rare with hydroquinone); skin irritation.
Store at room temperature (15°C–25°C), in original opaque container, protected from light and heat. Tretinoin is light-sensitive and degrades rapidly with light exposure. Do not freeze. Hydroquinone oxidizes to brown/black quinones on air or light exposure, indicating degradation. Keep tightly sealed. Use within the beyond-use date specified by Genesis Compounding.
Why is hydroquinone 6% used instead of the standard 4%?
Higher concentrations (6%) are prescribed for resistant or severe hyperpigmentation where lower concentrations have been ineffective. The prescriber weighs the increased efficacy against the higher risk of ochronosis and irritation. Treatment cycles are limited and monitored carefully.
What is ochronosis and how is it prevented?
Exogenous ochronosis is a rare, potentially permanent blue-black or gray-brown discoloration from homogentisic acid accumulation, associated with prolonged, high-concentration hydroquinone use. It is prevented by limiting treatment to 3–6 month cycles with rest periods, and by stopping treatment at the first sign of paradoxical darkening.
Do I need to use sunscreen?
Yes — sunscreen with SPF ≥30 broad-spectrum protection is mandatory daily throughout treatment and for several months after. Tretinoin increases UV sensitivity, and UV exposure directly stimulates melanogenesis, counteracting depigmenting therapy.
Is this FDA-approved?
No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding, not FDA-approved as a compounded drug.
Can I use this around my eyes?
No. Avoid eyes, nostrils, lips, and mucous membranes. Apply only to the targeted hyperpigmented skin areas as directed.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.